Results 121 to 130 of about 10,858 (213)

Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts [PDF]

BACKGROUND: Integrase strand-transfer inhibitors (INSTIs) and tenofovir alafenamide have been associated with weight gain in several clinical trials and observational cohorts.
Abela, I, Bansi-Matharu, L, Bissio, E, Byonanebye, DM, Castagna, A, Cohen, C, d'Arminio Monforte, A, De Wit, S, Fontas, E, Grabmeier-Pfistershammer, K, Hosein, SR, Jaschinski, N, Law, M, Maltez, F, Mocroft, A, Mussini, C, Peters, L, Petoumenos, K, Polizzotto, MN, Rauch, A, Ryom, L, Sarcletti, M, Vannappagari, V, Wasmuth, JC, Wit, F   +24 more
core  

Tenofovir alafenamide fumarate use for HIV pre-exposure prophylaxis and weight gain. [PDF]

Sci Rep
Shi F, Xia H, Weissman S, Li X, Yang X.
europepmc   +1 more source

Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg-Negative Patients With Normal Alanine Aminotransferase: A 48-Week Randomised Controlled Trial. [PDF]

J Viral Hepat
Luo Q, Xu W, Zhang Y, Li X, Lai J, Li J, Zheng X, Deng H, Chen L, Zhu X, Xie C, Peng L.   +11 more
europepmc   +1 more source

Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies. [PDF]

J Infect Dis
Cox S, Andreatta K, Hendricks MR, Li J, Kintu A, Brown LB, Carter CC, Callebaut C.   +7 more
europepmc   +1 more source

Evaluating the Efficacy of Crushed Bictegravir/Emtricitabine/Tenofovir Alafenamide Administered via Tube. [PDF]

Open Forum Infect Dis
Mercure J, Bey K, Gillett E, Pearson JC, McCluskey SM, Rock AE.   +5 more
europepmc   +1 more source

Eight-year Results from Two Randomized Phase 3 Trials of Tenofovir Alafenamide for Chronic Hepatitis B Virus Infection in China. [PDF]

J Clin Transl Hepatol
Hou J, Ning Q, Duan Z, Chen Y, Xie Q, Zhang L, Wu S, Tang H, Li J, Lin F, Yang Y, Gong G, Luo Y, Chen Y, Abramov F, Yee LJ, Wang H, Mateo R, Yazdi T, Botros I, Chen C, Huang Y, Zhang M, Jia J.   +23 more
europepmc   +1 more source

Efficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/immunosuppressive therapy. [PDF]

Hepatol Forum
Dilber F, Durak S, Unsal Y, Demir M, Yildirim AE, Ellik ZM, Mehdiyev S, Adanir H, Yapali S, Demirtas CO, Ucbilek E, Balaban Y, Ekmen N, Gokcan H, Koc ES, Dincer D, Sezgin O, Simsek H, Tozun N, Arslan M, Idilman R, Etik DO, Gokcen P, Ari D, Ozdil K, Akdogan M, Boyacioglu S.   +26 more
europepmc   +1 more source

Efficacy and Safety of Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate for Preventing Mother-to-Child Transmission of Hepatitis B in Treatment-Naïve mothers: An Observational Study. [PDF]

Virol J
Yang X, Chen J, Duan L, Li X, Cheng W, Chen Y, Huang Y, Huang Z.   +7 more
europepmc   +1 more source

Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe [PDF]

, 2017
, , Lodwick, R.
core   +1 more source

Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV in Asia: 24-Month findings from the observational BICSTaR study. [PDF]

Medicine (Baltimore)
Yang CJ, Kim YS, Choi JY, Choy CY, Lu PL, Tsai HC, Ryu J, Harrison R, Chang J, Mo B, Lee SH, Hung CC.   +11 more
europepmc   +1 more source